^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    18h
    GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Suspended, Mayo Clinic | Not yet recruiting --> Suspended
    Trial suspension
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab)
    18h
    KEYNOTE-G02: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=6, Terminated, Prelude Therapeutics | Trial completion date: Dec 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    Keytruda (pembrolizumab) • PRT3789
    19h
    Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=84, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Adcetris (brentuximab vedotin) • dexamethasone
    19h
    Modelling Immune Dynamics in Locally Advanced MSI-H/dMMR Colorectal Cancer with Neoadjuvant Pembrolizumab Treatment: From Differential Equations to an Agent-Based Framework. (PubMed, Bull Math Biol)
    On the other hand, agent-based models (ABMs) naturally capture stochasticity, interactions at an individual level, and discrete events that lie beyond the scope of differential-equation formulations. As such, we also convert our ODE model, with parameters calibrated to experimental data, to an ABM, preserving its dynamics while providing a flexible platform for future mechanistic investigation and modelling.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    19h
    Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. (PubMed, Adv Ther)
    Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KDR (Kinase insert domain receptor)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    20h
    KEYNOTE 426: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) (clinicaltrials.gov)
    P3, N=861, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • sunitinib • axitinib
    21h
    Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Chong Kun Dang Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Keytruda (pembrolizumab)
    22h
    Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    23h
    Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) (clinicaltrials.gov)
    P3, N=190, Active, not recruiting, Genmab | N=702 --> 190 | Trial completion date: Oct 2029 --> Sep 2028 | Trial primary completion date: Jun 2028 --> Jul 2027
    Enrollment change • Trial completion date • Trial primary completion date • Head-to-Head
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    1d
    Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody-drug conjugates, and clinical trial innovations. (PubMed, Front Oncol)
    The analysis focuses on treatments that have demonstrated clinical benefit in advanced or recurrent disease, including pembrolizumab, dostarlimab, tisotumab vedotin, and mirvetuximab soravtansine. Their growing integration into clinical practice has reshaped therapeutic approaches, while ongoing research continues to refine optimal combinations, address resistance, and enhance biomarker-guided selection. Future developments are expected to unite immunologic, genomic, and computational strategies to achieve personalized and durable outcomes for patients with gynecologic malignancies.
    Review • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FOLR1 ( Folate receptor alpha )
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • Elahere (mirvetuximab soravtansine-gynx) • Tivdak (tisotumab vedotin-tftv)
    2d
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)
    P3, N=255, Recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2026 --> Jan 2026
    Trial initiation date • pMMR
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2d
    PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov)
    P2, N=69, Terminated, Flamingo Therapeutics NV | Trial completion date: May 2026 --> Aug 2025 | Recruiting --> Terminated; Interim analysis was negative
    Trial completion date • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • danvatirsen (AZD9150)